Human iPSCs-derived endothelial cells with mutation in HNF1A as a model of maturity-onset diabetes of the young by Kachamakova-Trojanowska, Neli et al.
cells
Article
Human iPSCs-Derived Endothelial Cells with
Mutation in HNF1A as a Model of Maturity-Onset
Diabetes of the Young
Neli Kachamakova-Trojanowska 1,* , Jacek Stepniewski 2 and Jozef Dulak 1,2,3
1 Malopolska Centre of Biotechnology, Jagiellonian University, 30-387 Krakow, Poland; jozef.dulak@uj.edu.pl
2 Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology,
Jagiellonian University, 30-387 Krakow, Poland; jacek.stepniewski@uj.edu.pl
3 Kardio-Med Silesia, 41-800 Zabrze, Poland
* Correspondence: neli.kachamakova-trojanowska@uj.edu.pl; Tel.: +48126646412
Received: 13 September 2019; Accepted: 12 November 2019; Published: 14 November 2019 
Abstract: Patients with HNF1A-maturity-onset diabetes of the young (MODY) often develop
endothelial dysfunction and related microvascular complications, like retinopathy. As the clinical
phenotype of HNF1A-MODY diabetes varies considerably, we used human induced pluripotent stem
cells (hiPSCs) from two healthy individuals (control) to generate isogenic lines with mutation in
HNF1A gene. Subsequently, control hiPSCs and their respective HNF1A clones were differentiated
toward endothelial cells (hiPSC-ECs) and different markers/functions were compared. Human
iPSC-ECs from all cell lines showed similar expression of CD31 and Tie-2. VE-cadherin expression
was lower in HNF1A-mutated isogenic lines, but only in clones derived from one control hiPSCs.
In the other isogenic set and cells derived from HNF1A-MODY patients, no difference in VE-cadherin
expression was observed, suggesting the impact of the genetic background on this endothelial marker.
All tested hiPSC-ECs showed an expected angiogenic response regardless of the mutation introduced.
Isogenic hiPSC-ECs responded similarly to stimulation with pro-inflammatory cytokine TNF-α with
the increase in ICAM-1 and permeability, however, HNF1A mutated hiPSC-ECs showed higher
permeability in comparison to the control cells. Summarizing, both mono- and biallelic mutations
of HNF1A in hiPSC-ECs lead to increased permeability in response to TNF-α in normal glycemic
conditions, which may have relevance to HNF1A-MODY microvascular complications.
Keywords: iPSCs; endothelial cells; maturity-onset diabetes of the young (MODY); disease modeling;
HNF1A; CRISPR/Cas9; genetic background
1. Introduction
Diabetes is not only a metabolic disease, but is also considered as a vascular disease, due to its effect
on macro and microcirculation in many vascular beds. The link between diabetes and an increased
incidence of cardiovascular diseases is well established, however recently endothelial dysfunction (ED)
was shown to precede the clinical diagnosis of type 2 diabetes (T2D) by several years [1]. Despite
many proposed mechanisms for this relationship, the definitive pathogenesis remains unclear, possibly
because diabetes patients usually display multiple homeostatic imbalances alongside the typically
described hyperglycemia. Such disturbances induce ED independently of the presence of diabetes,
indicating a multifactorial etiology rather than hyperglycemia per se [2]. The mechanism of ED may
point at new management strategies for the prevention of cardiovascular disease in diabetes [1].
Monogenic forms of diabetes are invaluable "human models" that have contributed to our
understanding of the pathophysiological basis of common type 1 diabetes (T1D) and T2D [3]. However,
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research data on endothelial function in monogenic diabetes, such as maturity-onset diabetes of the
young (MODY), are so far very limited [4]. MODY is an autosomal dominant monogenic diabetic
disease typically affecting individuals before the age of 25 [5] and closely resembling T2D [6]. MODY
constitutes a heterogeneous group of relatively frequent autosomal single-gene disorders. Mutations
in the glucokinase (GCK) gene, along with hepatocyte nuclear factor 1A (HNF1A) gene, are the most
frequent causes of MODY [4]. Microvascular complications, particularly retinopathy, seem to be
common in HNF1A-MODY patients [7]. Despite a favorable lipid profile and decreased C-reactive
protein (CRP) level described in these patients, they can be characterized by an increased risk
of cardiovascular complications as compared with non-diabetic family members [8]. Therefore,
these complications seem to be mainly related to overall hyperglycemic exposure, rather than other
non-glycemic factors. However, there are studies describing polymorphism in HNF1A locus as a
risk factor for cardiovascular diseases [9,10]. The clinical expression in HNF1A-MODY patients is
highly variable from one family to another or even within the same family. HNF1A mutation carriers
may be normoglycemic, whereas their siblings may be hyperglycemic [11]. Therefore, it is not clear
whether the ED found in HNF1A-MODY patients [4] could be due to the diabetes complications or is
rather genetic consequence. It was recently shown that HNF1A-MODY patients have abnormalities in
endothelial function or/and presence of an early atherosclerotic phenotype [4]. Up to date, there are no
direct connections between ED and abnormal gene function in one of the most prevalent subtypes
of MODY.
Induced pluripotent stem cells (iPSCs) provide a well-defined source of tissue-specific cells and
are invaluable disease modeling tools. As HNF1A-MODY patients were shown to exhibit diabetic
microvascular complications [5], their iPSCs can be used to derive endothelial cells (ECs) and
investigate possible mechanisms contributing to the complications. However, the clinical phenotype
of HNF1A-MODY diabetes varies considerably [12], and studies examining correlations between
genotype and phenotype are still rare. Therefore, in the current study, we looked for possible ED using
iPSCs as disease modeling tools. HNF1A-MODY phenotype was modeled through the introduction
of mutations in HNF1A gene in two control human induced pluripotent stem cells (hiPSCs) lines,
using CRISPR/Cas9. Subsequently, all lines were differentiated toward ECs (hiPSC-ECs) and the
phenotype of the derived cells was compared. There was no difference in the expression of key
ECs markers like PECAM-1 (CD31), Tie-2, angiopoietins, von Willebrand Factor or endothelial nitric
oxide synthase (eNOS). However, in one of the control hiPSC-ECs and its respective mutated lines,
a clear difference in the expression level of VE-cadherin was found. This could not be confirmed
with another control line, suggesting that this effect is dependent on the genetic background of the
iPSCs. Importantly, differentiated cells responded appropriately to angiogenic stimuli independently
of HNF1A mutation. The same was true regarding ICAM-1 expression in response to pro-inflammatory
cytokine tumor necrosis factor alpha (TNF-α). However, hiPSC-ECs with HNF1A mutation showed
increased permeability after stimulation with TNF-α, which may have relevance to microvascular
complications in HNF1A-MODY diabetes [7].
2. Materials and Methods
2.1. Cells and Materials Used
Human-induced pluripotent stem cell line HPSI1013i-kuxp_1 (HipSci) was grown on geltrex-coated
6-well plates in E8 medium (ThermoFisher Scientific, Waltham, MA, USA). Control 2 hiPSCs line
was generated from peripheral blood mononuclear cells (PBMCs) collected from healthy volunteers
after obtaining informed consent (agreement from Jagiellonian University Bioethical Committee no.
122.6120.303.2016). PBMCs were reprogrammed using non-integrating Sendai vectors (Cytotune-iPS
2.0 Sendai Reprogramming kit, ThermoFisher Scientific, Waltham, MA, USA) according to the
manufacturer’s protocol (PBMC feeder-free system). MODY3a and MODY3b hiPSCs lines were
generated from fibroblasts isolated from two HNF1A-MODY patients as previously described [13]
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after obtaining informed consent (agreement from Jagiellonian University Bioethical Committee
no. KBET/43/B/2012). As in the case of PBMCs, cells were reprogrammed using non-integrating
Sendai vectors according to the manufacturer’s protocol (fibroblasts, feeder-free system). After
approximately three weeks, hiPSCs colonies were picked and expanded. The pluripotency of all
generated hiPSCs lines was confirmed before using the cells for further experiments (Supplementary
Figure S1). hiPSCs were cultured on geltrex-coated plates in an E8 medium. All cells were cultured at
37 ◦C in a humidified incubator with 5% CO2 (NuAire, Plymouth, MN, USA). TNF-α was purchased
from Shenandoah Biotechnology.
2.2. Derivation of Mutant hiPSCs
HPSI line was used to generate HNF1A-mutated lines using CRISPR/Cas9 gene-editing method.
For that purpose 5 × 105 cells were nucleofected with pLentiCRISPR v2-HNF1A-sgRNA1 (sgRNA
sequence: GTACGTCCGCAAGCAGCGAG; GenScript, Piscataway, NJ, USA) using Human Stem
Cell Nucleofector Kit 1 (Lonza) and program A023 on Nucleofector 2b device (Lonza, Basel,
Switzerland) [14] The used gRNA sequence was designed to uniquely target human HNF1A
gene and was additionally validated [15]. Similar strategy was applied for CIRSPR/Cas9-mediated
gene editing of HNF1A exon 2 in Control 2 hiPSCs line. To decrease the possibility of observing
off-target effects due to CRISPR/Cas9 modification, a different sgRNA was designed and applied
for Control 2 hiPSCs (sequence: CGGGAGGTGGTCGATACCAC). In this case, appropriate oligos
(5′-CACCGCGGGAGGTGGTCGATACCAC-3′ and 5′- AAACGTGGTATCGACCACCTCCCGC-3′)
were annealed cloned into pSpCas9(BB)-2A-Puro plasmid (Addgene #62988 [16], Watertown, MA,
USA) digested with BbsI restriction enzyme. Obtained plasmid was amplified and isolated with the
Plasmid Midi AX kit (A&A Biotechnology, Gdynia, Poland) according to the manufacturer’s protocol.
After nucleofection with the appropriate vectors, hiPSCs were seeded on a geltrex-coated well
of 12-well plate in the E8 medium supplemented with 10 µM ROCK inhibitor (Abcam, Cambridge,
UK). After 24h, the medium was replaced with fresh E8 supplemented with 0.5 µg/mL puromycin
(Sigma-Aldrich, St. Louis, Mo, USA) to select cells containing delivered plasmid. Subsequently,
the selecting medium was changed with fresh E8 after 24 h and hiPSCs were further cultured until
reaching approximately 80 % confluency. To obtain single cell-derived clones, nucleofected cells were
then harvested, counted and seeded on a geltrex-coated 10 cm plate (500 cells/plate) in E8 medium
supplemented with 10 µM ROCK inhibitor. After approximately 14 days clones were large enough to
be picked and further expanded.
To assess the presence of mutations in HNF1A locus and to verify whether these mutations were
introduced as monoallelic or biallelic, Guide it Genotype Confirmation Kit (TaKaRa, Kusatsu, Japan)
was used in the next step was used for HPSI cell line-derived clones. For that purpose, DNA was
isolated from each derived hiPSCs clone using Genomic Mini kit (A&A Biotechnology) according
to manufacturer’s instruction and subsequently subjected to PCR amplifying the region of HNF1A
gene containing putative mutations (primer forward: CCTTTATCTGTTCCAGTGTCTGT; primer
reverse: CAGGACCAAGTCTACTCCCGTC). PCR product solution was then incubated for 1h at 37 ◦C
with recombinant Cas9 nuclease bound to in vitro transcribed sgRNA sequence (the same as in the
pLentiCRISPR v2-HNF1-sgRNA1 plasmid, prepared with Guide-it sgRNA In Vitro Transcription kit
according to the company’s protocol). Upon inactivation of Cas9 nuclease (5 min, 80 ◦C), the samples
were run on 2% agarose gel. All steps were performed according to the instruction provided to the
Guide it Genotype Confirmation Kit. To confirm the presence of mutations in selected hiPSCs clones
from both control lines, Surveyor nuclease assay was further performed. For that purpose, isolated
DNA was subjected to PCR using the KAPA2G Fast Genotyping Mix (Sigma-Aldrich, St. Louis, Mo,
USA) and the same pair of primers as in Guide it Genotype Confirmation Kit. Subsequently, 9 µL of
PCR product solution was mixed with 1,5 µL CEL I buffer (custom made at the Department of Cell
Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow,
Poland) and subjected to heteroduplex formation upon heating to 95 ◦C and gradual decreasing
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the temperature to 25 ◦C. After heteroduplex formation, 1 µL of Celery Juice Extract (CJE, custom
made at the Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology,
Jagiellonian University, Krakow, Poland) and 3.5 µL of H2O was added and samples were incubated
at 45 ◦C for 45 min and run on 2% agarose gel. To assess the type of mutation introduced in the two
selected HPSI and Control 2-derived hiPSC clones, an amplified HNF1A region containing mutations
was sent for sequencing analysis (Genomed, Warsaw, Poland).
2.3. Differentiation toward Endothelial Cells (ECs)
All hiPSCs lines were differentiated based on previously published protocol [17] with modifications.
hiPSCs were seeded on geltrex-coated 12-well plates with cell density 1 × 105 cells/well in E8 medium
with 10 µM Y-27632 (Focus Biomolecules, Plymouth Meeting, PA, USA). Then the medium was
changed daily with E8 alone. On day 4, after reaching around 80–90% confluence, the medium was
changed to RPMI supplemented with B-27 without insulin (ThermoFisher Scientific, Waltham, MA,
USA) and 6 µM CHIR-99021 (Focus Biomolecules, Plymouth Meeting, PA, USA). Two days later the
medium was changed to RPMI supplemented with B-27 without insulin and 3 µM CHIR-99021 and
kept for 2 days when the medium was replaced by endothelial basic medium (Promocell, Heidelberg,
Germany) with 50 ng/mL VEGF (StemCell Technology, Vancouver, Canada) and 10 ng/mL bFGF
(StemCell Technology, Vancouver, Canada). On day 7 cells were detached with Accutase (Biowest,
Nuaille, France) and stained with CD31 (clone WM59, Biolegend, San Diego, CA, USA) and CD144
(clone 55-7H1, BD Biosciences, Franklin Lakes, NJ, USA). After washing the excess antibodies, CD31
positive cells were sorted using MoFlo cell sorter (Beckman Coulter, Brea, CA, USA) and cultured on
fibronectin-coated wells in endothelial growth medium (EGM MV2, Promocell, Heidelberg, Germany)
with the addition of 15 ng/mL VEGF – complete medium. Differentiated cells were used for experiments
in the first two weeks after sorting. The schematic representation of the differentiation procedure is
shown in Scheme 1.
Scheme 1. Schematic representation of the protocol used for endothelial differentiation of the human
induced pluripotent stem cells (hiPSC)s.
2.4. FACS Analysis
The expression of endothelial-specific surface proteins was assessed by flow cytometry. Briefly,
cells were detached with Accutase and after washing with PBS cells were stained with CD31, CD144,
Tie-2 (clone 33.1, Biolegend, San Diego, CA, USA), CD54 (ICAM-1, clone HCD54, Biolegend, San Diego,
CA, USA) in PBS + 2% FBS for 20 min at 4 ◦C in dark. Then excess antibodies were washed, and cells
were analyzed by flow cytometer BD Fortessa using DIVA software (BD Biosciences, Franklin Lakes,
NJ, USA). Dead cells were excluded from the analysis based on DAPI positive staining.
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2.5. Immunofluorescent Staining
For detection of intracellular as well as extracellular proteins, hiPSCs and iPSC-ECs were first
seeded on culture slides (BD Biosciences, Franklin Lakes, NJ, USA), then cultured for 24–72 h in
appropriate culture medium. The staining procedure was performed as described previously [18] with
the only change of TBS to PBS. All primary and secondary antibodies used in the current study are
listed in Table 1. Nuclei were stained with DAPI. Pictures were taken using an LSM 880 Zeiss confocal
microscope and analyzed with Zen 2.6 software (Zeiss, Oberkochen, Germany).
Table 1. List of all antibodies used for immunofluorescent stainings.
Species Company Dilution
Von Willebrand Factor Mouse ThermoFisher Scientific 1:50
Phospho-eNOS Rabbit ThermoFisher Scientific 1:70
VE-cadherin Mouse GeneTex 1:500
Angiopoietin 1 Rabbit Abcam 1:100
Angiopoietin 2 Rabbit Abcam 1:100
Oct-3/4 Goat Santa Cruz 1:200
Nanog Rabbit Abcam 1:100
SSEA-4 Mouse Millipore 1:100
TRA-1-60 Mouse Millipore 1:100
Anti-mouse–AF488, AF568 Goat Invitrogen 1:1000
Anti-rabbit-AF488, AF568 Goat Invitrogen 1:1000
Anti-goat AF488 Rabbit Invitrogen 1:1000
2.6. RNA Isolation and Real-Time PCR
RNA was isolated from hiPSC-ECs from both control lines and their respective isogenic
clones and subsequently reversed transcribed as described earlier [19]. The expression of CDH5
(VE-cadherin) was analyzed using Step One Plus real-time PCR (Applied Biosystems, Foster City,
CA, USA) with the addition of SYBR Green PCR Master Mix (SYBR®Green JumpStart™ Taq,
Sigma, St. Louis, Mo, USA). The following primer pairs for CHD5 were used: hVE-cad_F:
5′GCACCAGTTTGGCCAATATA3′; hVE-cad_R: 5′GGGTTTTTGCATAATAAGCAGG3′ [20]. The
expression of VE-cadherin was normalized to eukaryotic translation elongation factor 2 (EEF2 forward:
5′TCAGCACACTGGCATAGAGG 3′, reverse: 5′GACATCACCAAGGGTGTGCA3′) [19]. Gene
expression was calculated based on the comparative CT (threshold cycle value) method (∆CT = CT
gene of interest—CT housekeeping gene). The melting curve analysis was performed immediately
after each qPCR for the presence of primer-dimers or non-specific products.
2.7. Endothelial Sprouting Assay
The angiogenic sprouting assay was performed as previously described [13]. The basic medium
applied to solidified collagen was EBM with 0.5% FBS, whereas the complete medium was EGM MV2
+ 15 ng/mL VEGF. The sprouts were counted and measured after 24–48h. The lengths of sprouts were
calculated with AxioVision LE64 software (release 4.9.1 Zeiss, Oberkochen, Germany).
2.8. Matrigel Tube-Formation Assay
hiPSC-ECs were detached with Accutase and then 10,000 cells were seeded on the top of 50 µL
solidified Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) in complete medium (96-well plate) and
tube formation was assessed after 16–18 h culture using an inverted microscope.
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2.9. Permeability Assay
To assess endothelial permeability FITC-dextran permeabilization kit was used (Merck Millipore,
Darmstadt, Germany). Briefly, hiPSC-ECs were seeded on collagen-coated transwells for 72h in
complete medium. Then medium was gently changed to complete medium or stimulating medium
(complete medium + 100 ng/mL TNF-α) for 24 h, followed by incubation with FITC-dextran for 15 min
(following manufacturer’s instructions). The intensity of FITC fluorescence connected to the dextran,
which passed through the cell monolayer was measured with a Tecan multi-plate reader.
2.10. Statistical Analysis
All tests were performed at least in three independent differentiation experiments and statistical
significance was tested with t-test or one-way ANOVA (Graphpad, San Diego, CA, USA).
3. Results
3.1. Derivation of hiPSCs Lines with Mutation in HNF1A Gene and Proving Their Pluripotency
hiPSCs were used previously to study disease mechanisms of ECs [17,21]. One of the critical issues
with iPSC-based disease modeling is the use of the respective appropriate control [22]. In the current
study, we created isogenic lines by gene editing two hiPSCs lines from healthy individuals, looking
for mutation-specific changes unrelated to the individual genetic background. This isogenic iPSCs
approach bridges gap in the derivation of disease model from rare diseases with disease-associated
mutation, because of its relative ease of use and high efficiency.
The hiPSCs from HPSI control line were nucleofected with commercially available plasmids
encoding Cas9 and sgRNA targeting exon 2 and exon 4 of HNF1A gene and then selected with
puromycin. The hiPSCs control 2 line, from another healthy individual, was nucleofected with
pSpCas9(BB)-P2A-Puro encoding a different sgRNA sequence to additionally limit the risk that
observed changes were due to sgRNA-specific off-target effects. After the selection, cells were seeded in
lower density to obtain single-cell colonies, which were then expanded and used for isolation of DNA.
The introduction of mutations was checked with Guide-it™ Genotype Confirmation Kit (Figure 1A)
for HPSI-derived clones and surveyor assay (Figure 1B). Finally, the mutations in the chosen clones
from both control hiPSCs lines were confirmed by DNA sequencing (Figure 1C and Figure S1A). In the
clones derived from the HPSI line, there was monoallelic insertion of additional cysteine leading to
frameshift and premature stop codon (Figure 1C), similar to the mutations occurring in HNF1A-MODY
patients [23,24]. From the second control line, one clone had a heterozygous mutation with deletion of
13 nucleotides, leading to a premature STOP codon (monoallelic clone, MAC), whereas the second
clone had deletion of 13 nucleotides in both alleles of HNF1A (biallelic clone, BAC), (Figure S1A).
In order to check whether mutagenesis influenced hiPSCs pluripotency, iPSCs were stained for several
markers like OCT4, NANOG, SSEA-4, and TRA-1-60. There was no difference in the expression of
pluripotency markers between the control lines and the clones with HNF1A mutation (Figure 1D,
Figure S1B), showing that introduced mutations do not affect hiPSCs function.
The pluripotency of hiPSCs lines derived from two HNF1A-MODY patients (MODY3a and
MODY3b) were proven as well using the above mentioned pluripotent markers (Figure S1C).
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Figure 1. Generation of isogenic human induced pluripotent stem cell (hiPSC) lines; (A) results from
the Guide-it Genotype Confirmation kit, the red arrows show introduction of monoallelic mutation
in HPSI clones; (B) results from the surveyor assay of few selected clones, with asterisks showing
the cleaved products indicating the presence of heteroduplexes; (C) sequencing results from clone 4
(HPSI-derived clone) showing the introduction of the additional cysteine (red arrow), which leads to
frameshift and premature stop codon in one of HNF1A alleles; (D) staining of pluripotency markers
(NANOG, OCT-4, SSEA-4 and TRA-1-60) in HPSI control and HNF1A mutated hiPSCs lines.
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3.2. Mutation in HNF1A Does Not Have an Effect on the Expression of Several Endothelial-Specific Markers
Both control and mutated hiPSCs were successfully differentiated toward endothelial cells
(hiPSC-ECs), although the differentiation efficiency was different for the two control hiPSCs lines.
Higher efficiency was observed for hiPSCs control 2 line in comparison to the HPSI one (results
not shown), but no effect of HNF1A mutation on differentiation efficiency was found. hiPSC-ECs
from all lines expressed typical endothelial markers like PECAM-1 (CD31), CD144 (VE-cadherin) and
Tie-2 (Figure 2A,D). There was no difference in the expression levels of CD31 and Tie-2. Regarding
VE-cadherin expression, in HPSI lines two populations were clearly visible—with high and low
expression of the protein. Most of the cells with mutation in HNF1A showed lower expression
of VE-cadherin as compared to the control iPSC-ECs (Figure 2B). This decrease of VE-cadherin in
sgHNF1A lines was also visible on mRNA level (Figure 2C). However, hiPSC-ECs derived from the
control 2 line, had only one population with high VE-cadherin expression, which was not altered by the
monoallelic or biallelic mutation in HNF1A (Figure 2D,E). This lack of difference was confirmed also on
mRNA level (Figure 2F). Moreover, in hiPSC-ECs from two HNF1A-MODY patients, there was also no
difference in VE-cadherin expression (Figure 2D,E). Even a slight increase in the median fluorescence
intensity (MFI) in one of the HNF1A-MODY patients in comparison to control 2 was found (Figure 2E).
This strongly suggests, that the effect observed for VE-cadherin in HPSI line could be attributed to the
genetic background of this control line, which in combination with HNF1A mutation further impairs
VE-cadherin expression.
Other proteins like phospho-eNOS, von Willebrand factor, angiopoietin 1 and 2 were similarly
present in hiPSC-ECs from all lines (Figure S2A–D). Additionally, no visible change in VE-cadherin
localization between the hiPSC-ECs lines could be seen.
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Figure 2. Expression of endothelial markers in hiPSC-endothelial cells (ECs); (A) representative dot
plots from FACS analysis of CD31, Tie-2 and CD144 expression in control and HNF1A-mutated
hiPSC-ECs from HPSI control line; The gates in the lower panel show the clear difference in
VE-cadherin expression—cells with high and low (dim) expression are marked; (B) mean percentage
with SEM of two cell populations with high and low VE-cadherin expression in HPSI control line and
respective clones, based on FACS analysis, are presented from at least five independent differentiations,
*** p < 0.0005, **** p < 0.0001; (C) relative expression of VE-cadherin in hiPSC-ECs from HPSI control
and HNF1A-mutated lines, analyzed by real-time PCR; results are presented as 2−∆Ct where dots
represent means of at least 3 independent differentiation experiments; * p < 0.05; (D) representative dot
plots from FACS analysis of CD31, Tie-2 and CD144 expression in iPSC-ECs from control 2 together
with monoallelic (MAC) and biallelic mutated clones (BAC). In the right panel the expression of CD144
and CD31 of iPS-ECs from two HNF1A-MODY patients is presented; (E) median fluorescence intensity
of CD144 (VE-cadherin) of hiPSC-ECs from control 2 and its respective isogenic mutated lines – MAC
(monoallelic clone) and BAC, together with hiPSC-ECs from two HNF1A-MODY patients; * p < 0.05;
(F). Relative expression of VE-cadherin in hiPSC-ECs from control 2 and the isogenic clones MAC, and
BAC, analyzed by real-time PCR; results are presented as 2−∆Ct. No statistical difference between the
isogenic lines was found.
3.3. HNF1A Mutation Does Not Cause Differences in Angiogenic Capacity of Differentiated hiPSC-ECs
Apart from hyperglycemia, abnormalities of angiogenesis may cause or contribute toward many
of the clinical manifestations of diabetes. The main technical challenge in angiogenesis studies is the
selection of the most appropriate assay. As there is no “gold-standard” angiogenic assay, a combination
of assays is required [25]. The angiogenic capacity of differentiated cells was checked with two
commonly used in vitro assays. The tube-formation capacity of differentiated cells was independent of
the genetic background of the control line or the mutations in HNF1A gene (Figure 3A,B). Additionally,
the response of differentiated cells to angiogenic stimuli (like VEGF) was tested with endothelial
sprouting assay. hiPSC-ECs with and without mutation in HNF1A formed sprouts in the 3D collagen
matrix in response to angiogenic stimuli, which are included in the complete cell culture medium,
whereas no or less sprouts were observed when cells were cultured in basic medium (without growth
factors and lower FBS concentration, Figure 3C). There was no difference in the endothelial sprouting
assay response between the isogenic lines derived from HPSI hiPSCs line, both in basic and complete
medium, as measured by average sprout number/sphere (Figure 3D) and total sprout length/sphere
(Figure 3E). The results from both assays showed that mutations in HNF1A does not have an impact on
endothelial angiogenic capacity.
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Figure 3. Angiogenic capacity of hiPSC-ECs; (A) representative pictures of Matrigel tube-formation
assay of cells with heterozygous mutation in HNF1A gene together with the respective HPSI control
cells (upper panel—magnification 40×, lower panel—agnification 100×); (B) representative pictures of
Matrigel tube-formation assay of cells with monoallelic (MAC) and biallelic (BAC) mutation in HNF1A
gene with the respective control 2 cells (upper panel—magnification 40×, lower panel—magnification
100×); (C) representative pictures of spheres formed by hiPSC-ECs in basic medium (BM) and in
complete medium (CM); (D) calculation of the mean number of sprouts/sphere (±SEM); (E) total sprout
length per sphere (±SEM). For (D) and (E) summarized data from both clone 4 and clone 6 are presented
as sgHNF1A. No statistical difference in angiogenic capacity between the lines could be observed.
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3.4. Differentiated Cells Respond Appropriately to Pro-Inflammatory Cytokine with No Effect of HNF1A
Mutation
Another feature of the mature endothelium is the ability to respond to pro-inflammatory stimuli
and participate in the inflammatory reaction. Under normal physiological conditions, the endothelium
is in a quiescent and anti-inflammatory state, however, in the presence of risk factors, it can be
activated to express adhesion molecules like intracellular adhesion molecule-1 (ICAM-1) [26]. These
molecules are required for communication of the endothelium with the immune system (leukocytes).
Additionally, it is known that there is an increase in pro-inflammatory cytokines like TNFα in diabetic
retinopathy [27]. Therefore, we checked the expression of ICAM-1 in basic conditions and after
stimulation with 20 ng/mL TNFα There was no difference in ICAM-1 expression in basic conditions
related to HNF1A mutation, seen for both control lines and their respective mutated clones (Figure 4A).
All cell lines responded with an appropriate increase in ICAM-1 expression when treated with TNFα
(Figure 4B), but no difference in this response in relation to HNF1A mutation could be observed
(Figure 4C,D).
Figure 4. Response to pro-inflammatory cytokine (TNFα); (A) median fluorescence intensity (MFI) of
ICAM-1 in hiPSC-ECs cultured in basic conditions (complete medium)—mean ± SEM, data is taken
from at least 3 independent differentiation experiments; (B) representative dot plot; (C) increase in
ICAM-1 expression presented as percentage from respective control cells (cells not treated with the
cytokine), showing no difference in ICAM-1 increase between the normal hiPSC-ECs and cells with
introduced mutation in HNF1A gene (sgHNF1A shows summarized data from both clones); (D) increase
in ICAM-1 expression presented as percentage from respective control cells (cells not treated with the
cytokine), showing no difference in ICAM-1 increase between the normal hiPSC-ECs (control 2) and
cells with monoallelic or biallelic mutation in HNF1A gene.
Cells 2019, 8, 1440 13 of 18
3.5. Increased Permeability of hiPSC-ECs with Mutation in HNF1A After Pro-Inflammatory Stimuli
In response to TNFα, ECs respond not only with increased expression in adhesion molecules but
also with increased permeability. Additionally, it is known that the consequences of the biochemical
changes in diabetic retinopathy, like inflammation and oxidative stress, lead to vascular permeability
and capillary rarefaction [28]. Therefore, we looked at the vascular permeability of iPSC-ECs in
response to pro-inflammatory cytokine. Results show that in all hiPSC-ECs there was an increase
in vascular permeability after TNFα stimulation (Figure 5A). However, the cells with heterozygous
mutation in HNF1A responded with a much higher increase in vascular permeability (Figure 5B),
pointing at certain susceptibility of HNF1A-MODY ECs to diabetic complications as diabetic retinopathy.
Importantly, the same effect was observed with the second set of isogenic lines (Figure 5C). Moreover,
this increase was the highest, when HNF1A was mutated in both alleles, pointing at a strong relation
between the increased endothelial permeability and HNF1A mutations.
Figure 5. Permeability assay of hiPSC-ECs; (A) TNFα causes increase in endothelial permeability as
measured by the increase in FITC-dextran fluorescence intensity in all tested lines, data presented as
means±SEM, * p < 0.05, ** p < 0.01; (B) Increased permeability after stimulation with TNFα in hiPSC-ECs
with mutation in HNF1A in comparison to the non-mutated cells, data is presented as percentage from
the respective controls (cells cultured in complete medium without cytokine stimulation), where dots
are means ± SEM, * p < 0.05; (C) Increased permeability after stimulation with TNFα in hiPSC-ECs
with monoallelic or biallelic mutation in HNF1A in comparison to the non-mutated cells, data are
presented as percentage from the respective controls (cells cultured in complete medium without
cytokine stimulation), where dots are means ± SEM, * p < 0.05; ** p < 0.01.
4. Discussion
As abnormal endothelial physiology may cause wide-spread systemic diseases and also play a
crucial role in a variety of human disorders, many studies used hiPSCs as modeling tools regarding
ED [29]. It is currently clear that subtle microvascular dysfunctions may precede diabetes and also
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may predict common clinical complications like retinopathy and nephropathy [30]. Additionally,
normal microvascular function is necessary for physiological insulin-mediated glucose disposal and
glucose-induced insulin secretion, highlighting that association between ED and hyperglycemia in T2D
is bidirectional [30]. Therefore, in the current study, we investigated for subtle changes in endothelial
function of cells with HNF1A mutation, looking for possible pathological readout connected to diabetic
retinopathy, as it is a common complication in patients with HNF1A-MODY. Using isogenic cell lines
to limit the effect of the genetic background [31] we checked the expression of endothelial markers and
focused on cells’ responses to pro-angiogenic and pro-inflammatory stimulations.
Multiple protocols have been established for differentiation of iPSCs into ECs [17,32–34], although
still efforts are made to make the methods more reproducible and with higher yield [29]. Most of the
published protocols differ in efficiency, cost, complexity, and variability, therefore commonly the proper
choice of EC differentiation protocol depends on the downstream application [35]. In the current study
the modified protocol of Gu et al., for EC differentiation was used [17]. Modifying the protocol allowed
for the increase of the yield from 1–2% to 20–25 %. Using this protocol for all generated hiPSCs lines,
no difference in the differentiation capacity toward endothelium, connected to HNF1A mutations,
was found.
Differentiated iPSC-ECs showed expression of typical endothelial markers like CD31, Tie-2,
angiopoietins (1 and 2) and von Willebrand Factor. PECAM-1 (CD31) is highly expressed at
ECs intercellular junctions and has multiple functions like regulation of leukocyte trafficking and
maintenance of EC junctional integrity [36]. There was no difference in CD31 expression between ECs
with and without HNF1A mutation. Angiopoietins (Ang) act through the tyrosine kinase receptor
Tie-2, which in turn regulates survival, apoptosis, regulates capillary sprouting or controls vascular
permeability [37]. Ang1 is a potent angiogenic growth factor, whereas Ang 2 was considered as
antagonist acting through the same receptor, Tie-2. In the current study, no difference in the expression
of Ang1 or Tie-2 in hiPSC-ECs with and without HNF1A mutation was found. However, recent data
points at the more important role of Ang 2 in EC pathophysiology, as its dysregulated expression was
found in several disorders like cardiovascular diseases, diabetic retinopathy and obesity [38]. Ang 2
was found to facilitate angiogenesis, vascular permeability and inflammation under certain disease
settings [39]. Nevertheless, HNF1A mutation did not cause any visible difference in Ang 2 expression
in hiPSC-ECs, however additional and more precise evaluation of Ang 2 expression would be needed
to confirm the lack of difference in this protein.
VE-cadherin is a very specific endothelial junction molecule with vital importance in maintaining
and controlling ECs contacts [40]. It is known that cells modulate their adhesive state by controlling
the amount of cadherin localized at the cell surface. The expression of VE-cadherin can be regulated
via internalization or by shedding by specific disintegrins and metalloproteinases [41,42]. In previous
studies, it was found that patients with T2D have increased levels of plasma VE-cadherin levels [43].
Soluble VE-cadherin can be released in the bloodstream after increased proteolitic activity of ADAM
10 due to inflammation, thus leading to increased permeability [42,44,45]. At this stage, there are no
studies showing any connection between soluble VE-cadherin and microvascular complications in
HNF1A-MODY patients. In the current study, controversial results for VE-cadherin expression were
found. The impact of the genetic background of the hiPSCs lines was apparent, as no changes could
be observed with cells from one control line together with its respective isogenic mutated clones and
in two HNF1A-MODY patients. However, when another control hiPSCs line was used, where two
distinct populations of cells (with low and high VE-cadherin expression) were present in the control
line, a significant decrease in VE-cadherin was found in HNF1A mutated clones, both on protein and
mRNA levels. Therefore, it could be speculated that the altered VE-cadherin expression, observed in
isogenic cell lines derived from the HPSI control line, is a result of the additive impact of the donor
genetic background and the HNF1A mutation. This indicates that for proper disease modeling of
monogenic diseases, where the genetic background could play a significant role together with the
mutation in a certain gene, the results from several hiPSCs lines should be taken into consideration.
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VE-cadherin participates in multiple aspects of EC biology like maturation, remodeling, and
extension of vessels, which are characteristics of angiogenesis [41]. Physiological angiogenesis is a
highly organized sequence of cellular events, which are controlled and modulated to meet the tissue
requirements. The angiogenesis process is, however, also implicated in the pathogenesis of vascular
abnormalities of the retina, kidneys, and fetus, impaired wound healing, increased risk of rejection
of transplanted organs, and impaired formation of coronary collaterals. A perplexing feature of the
aberrant angiogenesis is that excessive and insufficient angiogenesis can occur in different organs in
the same individual [46]. In patients with HNF1A-MODY almost every fourth diagnosed individual
shows diabetic retinopathy [7], which could be associated with increased VEGF production and
neovascularization [47]. In the current study, there was no difference in the angiogenic properties of
hiPSC-ECs with and without mutation in the HNF1A gene. Using two in vitro tests we show that
hiPSC-ECs from all lines respond appropriately to pro-angiogenic factors. In our previous study
we have shown that iPSC-EC from murine genetic model of diabetes (db/db mice) have impaired
angiogenic capacity in comparison to cells from wild type mice and these findings were confirmed
with primary cells isolated from lungs [13], proving that iPSCs-derived ECs can be successfully used as
disease modeling tools. Thus, based on our current results, it can be suggested that HNF1A mutation
does not cause any direct impairment of the angiogenic response of human ECs.
In diabetic retinopathy, there is an increase of pro-inflammatory cytokines and chemokines like
monocyte chemoattractant protein 1, TNFα, interleukin 1β (IL-1β) and IL-6 [39]. Therefore, we looked
for the hiPSC-ECs response to TNFα. Cells from all lines responded appropriately to pro-inflammatory
stimulation with the upregulation of ICAM-1, but this increase was not affected by the introduced
HNF1A mutation. However, the vascular permeability of ECs with HNF1A monoallelic mutation was
higher than the permeability of the control cells. In diabetic retinopathy dysfunction of vascular cells
in the inner blood-retinal barrier leads to a breakdown of this barrier resulting in vascular leakage
and as a consequence vision impairment [28]. A major risk factor for diabetic retinopathy is sustained
hyperglycemia, however, certain diabetic populations do not develop such complications, whereas
good glycemic control may not eliminate the life-time risk for retinopathy. Altogether, this suggests
that there are additional factors, such as genetic susceptibility involved in the initiation and progression
of diabetic retinopathy [39].
5. Conclusions
In the current study, we have shown for the first time that iPSCs-derived ECs with HNF1A
mutations have increased permeability in response to TNFα. Importantly, this increase could be
detected with both mono- and biallelic mutation clones, independently of the genetic background and
as a sole response to pro-inflammatory stimulation. Therefore, it could be suggested that mutations in
the HNF1A gene, as occurring in HNF1A-MODY patients, could predispose for increased vascular
permeability and subsequent microvascular complications.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/11/1440/s1.
Author Contributions: Conceptualization, N.K.T. and J.D.; methodology, N.K.-T. and J.S.; formal analysis, N.K.-T.
and J.S.; investigation, N.K.-T. and J.S.; data curation, N.K.-T. and J.S.; writing—original draft preparation, N.K.-T.
and J.S.; writing—review and editing, N.K.-T., J.S., J.D.; visualization, N.K.-T. and J.S.; supervision, J.D.; project
administration, N.K.-T.; funding acquisition, N.K.-T.
Funding: The work was supported by National Science Center Opus research grant 2016/23/B/NZ1/01804.
Acknowledgments: The technical work of Benjamin Motais and Eleder Cachorro Puente in generation of the
isogenic hiPSCs lines is highly acknowledged.
Conflicts of Interest: The authors declare no conflict of interest.
Cells 2019, 8, 1440 16 of 18
References
1. Sena, C.M.; Pereira, A.M.; Seiça, R. Endothelial dysfunction—A major mediator of diabetic vascular disease.
Biochim. Biophys. Acta Mol. Basis Dis. 2013, 1832, 2216–2231. [CrossRef] [PubMed]
2. Roberts, A.C.; Porter, K.E. Cellular and molecular mechanisms of endothelial dysfunction in diabetes.
Diabetes Vasc. Dis. Res. 2013, 10, 472–482. [CrossRef] [PubMed]
3. Yang, Y.; Chan, L. Monogenic Diabetes: What It Teaches Us on the Common Forms of Type 1 and Type 2
Diabetes. Endocr. Rev. 2016, 37, 190–222. [CrossRef] [PubMed]
4. Szopa, M.; Osmenda, G.; Wilk, G.; Matejko, B.; Skupien, J.; Zapala, B.; Młynarski, W.; Guzik, T.; Malecki, M.T.
Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients. Eur. J. Endocrinol.
2015, 172, 277–283. [CrossRef]
5. Teo, A.K.K.; Windmueller, R.; Johansson, B.B.; Dirice, E.; Njolstad, P.R.; Tjora, E.; Raeder, H.; Kulkarni, R.N.
Derivation of Human Induced Pluripotent Stem Cells from Patients with Maturity Onset Diabetes of the
Young. J. Biol. Chem. 2013, 288, 5353–5356. [CrossRef]
6. Bellanné-Chantelot, C.; Lévy, D.J.; Carette, C.; Saint-Martin, C.; Riveline, J.-P.; Larger, E.; Valéro, R.;
Gautier, J.-F.; Reznik, Y.; Sola, A.; et al. Clinical characteristics and diagnostic criteria of maturity-onset
diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J. Clin. Endocrinol. Metab.
2011, 96, E1346–E1351. [CrossRef]
7. Szopa, M.; Wolkow, J.; Matejko, B.; Skupien, J.; Klupa, T.; Wybran´ska, I.; Trznadel-Morawska, I.;
Kiec-Wilk, B.; Borowiec, M.; Malecki, M.T. Prevalence of Retinopathy in Adult Patients with GCK-MODY
and HNF1A-MODY. Exp. Clin. Endocrinol. Diabetes 2015, 123, 524–528. [CrossRef]
8. Steele, A.M.; Shields, B.M.; Shepherd, M.; Ellard, S.; Hattersley, A.T.; Pearson, E.R. Increased all-cause and
cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet. Med.
2010, 27, 157–161. [CrossRef]
9. O’Donnell, C.J.; Nabel, E.G. Genomics of Cardiovascular Disease. N. Engl. J. Med. 2011, 365, 2098–2109.
[CrossRef]
10. Wakil, S.M.; Muiya, N.P.; Tahir, A.I.; Al-Najai, M.; Baz, B.; Andres, E.; Mazhar, N.; Al Tassan, N.; Alshahid, M.;
Meyer, B.F.; et al. A New Susceptibility Locus for Myocardial Infarction, Hypertension, Type 2 Diabetes
Mellitus, and Dyslipidemia on Chromosome 12q24. Dis. Markers 2014, 2014, e291419. [CrossRef]
11. Steck, A.K.; Winter, W.E. Review on monogenic diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18,
252–258. [CrossRef] [PubMed]
12. Galán, M.; García-Herrero, C.-M.; Azriel, S.; Gargallo, M.; Durán, M.; Gorgojo, J.-J.; Andía, V.-M.; Navas, M.-A.
Differential effects of HNF-1α mutations associated with familial young-onset diabetes on target gene
regulation. Mol. Med. 2011, 17, 256–265. [CrossRef] [PubMed]
13. Stepniewski, J.; Kachamakova-Trojanowska, N.; Ogrocki, D.; Szopa, M.; Matlok, M.; Beilharz, M.; Dyduch, G.;
Malecki, M.T.; Jozkowicz, A.; Dulak, J. Induced pluripotent stem cells as a model for diabetes investigation.
Sci. Rep. 2015, 5, 8597. [CrossRef] [PubMed]
14. Kime, C.; Mandegar, M.A.; Srivastava, D.; Yamanaka, S.; Conklin, B.R.; Rand, T.A. Efficient
CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells. Curr. Protoc. Hum. Genet. 2016,
88, 21.4.1–21.4.23.
15. Sanjana, N.E.; Shalem, O.; Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening.
Nat. Meth. 2014, 11, 783–784. [CrossRef]
16. Ran, F.A.; Hsu, P.D.; Wright, J.; Agarwala, V.; Scott, D.A.; Zhang, F. Genome engineering using the
CRISPR-Cas9 system. Nat. Protoc. 2013, 8, 2281–2308. [CrossRef]
17. Gu, M.; Shao, N.-Y.; Sa, S.; Li, D.; Termglinchan, V.; Ameen, M.; Karakikes, I.; Sosa, G.; Grubert, F.; Lee, J.;
et al. Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary
Hypertension in BMPR2 Mutation Carriers. Cell Stem Cell 2017, 20, 490–504. [CrossRef]
18. Kachamakova-Trojanowska, N.; Nowak, W.; Szade, K.; Stepniewski, J.; Bukowska-Strakova, K.; Zukowska, M.;
Taha, H.; Chmura-Skirlinska, A.; Beilharz, M.; Dulak, J.; et al. Generation of functional endothelial cells with
progenitor-like features from murine induced pluripotent stem cells. Vascul. Pharmacol. 2016, 86, 94–108.
[CrossRef]
Cells 2019, 8, 1440 17 of 18
19. Kachamakova-Trojanowska, N.; Jazwa-Kusior, A.; Szade, K.; Kasper, L.; Soja, J.; Andrychiewicz, A.; Jakiela, B.;
Plutecka, H.; Sanak, M.; Jozkowicz, A.; et al. Molecular profiling of regulatory T cells in pulmonary sarcoidosis.
J. Autoimmun. 2018, 94, 56–69. [CrossRef]
20. Kiran, M.S.; Viji, R.I.; Kumar, S.V.; Prabhakaran, A.A.; Sudhakaran, P.R. Changes in expression of VE-cadherin
and MMPs in endothelial cells: Implications for angiogenesis. Vasc. Cell 2011, 3, 6. [CrossRef]
21. Sekine, S.-I.; Nishii, K.; Masaka, T.; Kurita, H.; Inden, M.; Hozumi, I. SLC20A2 variants cause dysfunctional
phosphate transport activity in endothelial cells induced from Idiopathic Basal Ganglia Calcification
patients-derived iPSCs. Biochem. Biophys. Res. Commun. 2019, 510, 303–308. [CrossRef] [PubMed]
22. Doss, M.X.; Sachinidis, A. Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications.
Cells 2019, 8, 403. [CrossRef] [PubMed]
23. Yamagata, K.; Yang, Q.; Yamamoto, K.; Iwahashi, H.; Miyagawa, J.; Okita, K.; Yoshiuchi, I.; Miyazaki, J.;
Noguchi, T.; Nakajima, H.; et al. Mutation P291fsinsC in the transcription factor hepatocyte nuclear
factor-1alpha is dominant negative. Diabetes 1998, 47, 1231–1235. [CrossRef]
24. Pace, N.P.; Rizzo, C.; Abela, A.; Gruppetta, M.; Fava, S.; Felice, A.; Vassallo, J. Identification of an HNF1A
p.Gly292fs Frameshift Mutation Presenting as Diabetes During Pregnancy in a Maltese Family. Clin. Med.
Insights Case Rep. 2019, 12. [CrossRef]
25. Staton, C.A.; Reed, M.W.R.; Brown, N.J. A critical analysis of current in vitro and in vivo angiogenesis assays.
Int. J. Exp. Pathol. 2009, 90, 195–221. [CrossRef]
26. Tabit, C.E.; Chung, W.B.; Hamburg, N.M.; Vita, J.A. Endothelial dysfunction in diabetes mellitus: Molecular
mechanisms and clinical implications. Rev. Endocr. Metab. Disord. 2010, 11, 61–74. [CrossRef]
27. Li, J.; Wang, J.J.; Yu, Q.; Wang, M.; Zhang, S.X. Endoplasmic reticulum stress is implicated in retinal
inflammation and diabetic retinopathy. FEBS Lett. 2009, 583, 1521–1527. [CrossRef]
28. Shin, E.S.; Sorenson, C.M.; Sheibani, N. Diabetes and Retinal Vascular Dysfunction. J. Ophthalmic Vis. Res.
2014, 9, 362–373.
29. Jang, S.; de l’Hortet, A.C.; Soto-Gutierrez, A. Induced Pluripotent Stem Cell–Derived Endothelial Cells:
Overview, Current Advances, Applications, and Future Directions. Am. J. Pathol. 2019, 189, 502–512.
[CrossRef]
30. Stehouwer, C.D.A. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle with Widespread
Consequences. Diabetes 2018, 67, 1729–1741. [CrossRef]
31. Bassett, A.R. Editing the genome of hiPSC with CRISPR/Cas9: Disease models. Mamm. Genome 2017, 28,
348–364. [CrossRef]
32. Orlova, V.V.; van den Hil, F.E.; Petrus-Reurer, S.; Drabsch, Y.; Ten Dijke, P.; Mummery, C.L. Generation,
expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem
cells. Nat. Protoc. 2014, 9, 1514–1531. [CrossRef] [PubMed]
33. Patsch, C.; Challet-Meylan, L.; Thoma, E.C.; Urich, E.; Heckel, T.; O’Sullivan, J.F.; Grainger, S.J.; Kapp, F.G.;
Sun, L.; Christensen, K.; et al. Generation of vascular endothelial and smooth muscle cells from human
pluripotent stem cells. Nat. Cell Biol. 2015, 17, 994–1003. [CrossRef]
34. Liu, X.; Qi, J.; Xu, X.; Zeisberg, M.; Guan, K.; Zeisberg, E.M. Differentiation of functional endothelial cells from
human induced pluripotent stem cells: A novel, highly efficient and cost effective method. Differentiation
2016, 92, 225–236. [CrossRef] [PubMed]
35. Williams Ian, M.; Wu Joseph, C. Generation of Endothelial Cells from Human Pluripotent Stem Cells.
Arterioscler. Thromb. Vasc. Biol. 2019, 39, 1317–1329. [CrossRef]
36. Privratsky, J.R.; Newman, P.J. PECAM-1: Regulator of endothelial junctional integrity. Cell Tissue Res. 2014,
355, 607–619. [CrossRef] [PubMed]
37. Martin, V.; Liu, D.; Fueyo, J.; Gomez-Manzano, C. Tie2: A journey from normal angiogenesis to cancer and
beyond. Histol. Histopathol. 2008, 23, 773–780.
38. Akwii, R.G.; Sajib, M.S.; Zahra, F.T.; Mikelis, C.M. Role of Angiopoietin-2 in Vascular Physiology and
Pathophysiology. Cells 2019, 8, 471. [CrossRef]
39. Kusuhara, S.; Fukushima, Y.; Ogura, S.; Inoue, N.; Uemura, A. Pathophysiology of Diabetic Retinopathy:
The Old and the New. Diabetes Metab. J. 2018, 42, 364–376. [CrossRef]
40. Vestweber, D. VE-cadherin: The major endothelial adhesion molecule controlling cellular junctions and
blood vessel formation. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 223–232. [CrossRef]
Cells 2019, 8, 1440 18 of 18
41. Harris, E.S.; Nelson, W.J. VE-Cadherin: At the Front, Center, and Sides of Endothelial Cell Organization and
Function. Curr. Opin. Cell Biol 2010, 22, 651–658. [CrossRef]
42. Flemming, S.; Burkard, N.; Renschler, M.; Vielmuth, F.; Meir, M.; Schick, M.A.; Wunder, C.; Germer, C.-T.;
Spindler, V.; Waschke, J.; et al. Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic
inflammation and sepsis. Cardiovasc. Res. 2015, 107, 32–44. [CrossRef] [PubMed]
43. Yan, Y.; Chang, Q.; Li, Q.; Li, L.; Wang, S.; Du, R.; Hu, X. Identification of plasma vascular endothelia-cadherin
as a biomarker for coronary artery disease in Type 2 diabetes mellitus patients. Int. J. Clin. Exp. Med. 2015, 8,
19466–19470.
44. Donners, M.M.; Wolfs, I.M.; Olieslagers, S.; Mohammadi-Motahhari, Z.; Tchaikovski, V.; Heeneman, S.;
van Buul, J.D.; Caolo, V.; Molin, D.G.; Post, M.J.; et al. A Disintegrin and Metalloprotease 10 Is a Novel
Mediator of Vascular Endothelial Growth Factor—Induced Endothelial Cell Function in Angiogenesis and Is
Associated with Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2188–2195. [CrossRef] [PubMed]
45. Dreymueller, D.; Pruessmeyer, J.; Groth, E.; Ludwig, A. The role of ADAM-mediated shedding in vascular
biology. Eur. J. Cell Biol. 2012, 91, 472–485. [CrossRef]
46. Kota, S.K.; Meher, L.K.; Jammula, S.; Kota, S.K.; Krishna, S.V.S.; Modi, K.D. Aberrant angiogenesis:
The gateway to diabetic complications. Indian J. Endocrinol. Metab. 2012, 16, 918–930. [CrossRef]
47. Fowler, M.J. Microvascular and Macrovascular Complications of Diabetes. Clin. Diabetes 2008, 26, 77–82.
[CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
